Wolfgang Schmitt

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

Carsten Denkert, Gϋnter von Minckwitz, Silvia Darb‐Esfahani et al. · The Lancet Oncology · 2017 · 2.1K citations

Medicine, Immunology, Oncology +14

Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization

Jan Budczies, Frederick Klauschen, Bruno V. Sinn et al. · PLoS ONE · 2012 · 1.3K citations · Full text

Pharmacy, Bioinformatics, Biostatistics +17

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

Carsten Denkert, Gϋnter von Minckwitz, Jan C. Brase et al. · Journal of Clinical Oncology · 2014 · 1K citations · Full text

Medicine, Immunology, Oncology +17

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

S. Loibl, Michael Untch, Nicole Burchardi et al. · Annals of Oncology · 2019 · 694 citations

Medicine, Oncology, Pharmacology +16

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

Carsten Denkert, Fenja Seither, Andreas Schneeweiß et al. · The Lancet Oncology · 2021 · 561 citations

Medicine, Cancer Biology, Oncology +16